3832results about "Ester active ingredients" patented technology

The invention discloses a method for preparing diglyceride with the effects of reducing blood fat, total cholesterol, blood sugar and uric acid through enzymolysis and a product and application of the diglyceride, and belongs to the technical field of diglyceride production.The method comprises the following steps that 1, vegetable oil, glycerin, compound lipase and water are mixed to be subjected to a glycerolysis reaction, and a reactant is obtained; (2) separating reactants, and collecting supernatant; (3) performing distillation separation on the supernatant, and performing decoloration and deodorization to obtain diglyceride; the vegetable oil in the step (1) is low-erucic acid rapeseed oil and corn oil; the composite lipase in the step (1) is prepared from mucor javanicus lipase, aspergillus niger lipase and aspergillus oryzae lipase in a mass ratio of (2-4): 1: (5-8). According to the invention, the use amount of enzyme can be reduced, the cost is reduced, and the prepared diglyceride has better activity of reducing blood fat, total cholesterol, blood sugar and uric acid, and has more advantages in the preparation of health care products.

Pharmaceutical compositions of epinephrine and its prodrugs are described and the compositions having enhanced active component permeation properties are described as being administered with specific residence times.

Disclosed herein are “ketone body-HMB” or “KB-HMB” compositions including a combination of: (1) hydroxymethyl butyrate; (2) a ketone body component such as beta-hydroxybutyrate (BHB) and / or acetoacetate; and (3) optionally a dietetically or pharmaceutically acceptable carrier. Also disclosed herein are methods of using such compositions for producing desired physiological effects, such as fat loss, in a mammal. The compositions beneficially enhance fat loss through ketosis while also reducing or eliminating muscle wasting and / or promoting muscle formation.

Pharmaceutical compositions including N-N-dimethyltryptamine (DMT) acceptable salt or prodrug thereof in combination with an antihypertensive agent to reduce sympathomimetic effects associated with the administration of DMT.

The invention belongs to the technical field of grease chemistry, and particularly relates to diglyceride prepared through enzymolysis and used for reducing blood fat, a preparation method and application of the diglyceride. The preparation method comprises the following steps: (1) mixing edible oil, lipase and water, hydrolyzing and dehydrating to obtain a hydrolysate; and (2) mixing the hydrolysate, glycerol and partial glyceride lipase, reacting, and distilling to obtain the diglyceride, the partial glyceride lipase in the step (2) is a mixture of lipase Lipase G50 and lipase Novozyme 435. The diglyceride prepared by the method disclosed by the invention has an excellent effect of reducing blood fat; and the obtained diglyceride is high in yield and low in acid value, and the finished product does not need deacidification treatment, so that the method is suitable for large-scale industrial production.

Compositions for inducing and maintaining a state of flow in a subject include optically pure S-beta-hydroxybutyrate or non-racemic mixtures enriched with the S-enantiomer. The S-beta-hydroxybutyrate enantiomer modulates the effect of ketone bodies in the subject and controls the rate at which ketosis is achieved. Beta-hydroxybutyric acid is more rapidly absorbed and utilized by the body than salts or esters, enhances taste, and reduces the need to include citric acid or other edible acids. Beta-hydroxybutyrate salts are more slowly absorbed and utilized by the body and can provide one or more electrolytes. Compositions for controlling ketone body level in a subject may contain a dietetically or pharmaceutically acceptable carrier and optically pure S-beta-hydroxybutyrate or non-racemic mixture enriched with S-beta-hydroxybutyrate, wherein the compositions contain from about 50.5% to 100% by enantiomeric equivalents of S-beta-hydroxybutyrate and from about 49.5% to 0% by enantiomeric equivalents of R-beta-hydroxybutyrate.

Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.

The present invention relates to a nutritional composition, food and pharmaceutical products comprising the nutritional composition, and uses thereof. The nutritional composition comprises medium and long chain fatty acid triglycerides and breast milk oligosaccharides, and the weight ratio of the medium and long chain fatty acid triglycerides to the breast milk oligosaccharides is 1: 1 to 9: 1. The nutritional composition disclosed by the invention can play a role in synergistically promoting skeletal development and particularly improving bone mineral density.

The invention relates to the technical field of food, in particular to diglyceride for reducing triglyceride, cholesterol and uric acid as well as a biological enzyme preparation method and application of the diglyceride. The preparation method comprises the following steps: (1) adding water and glycerol into vegetable oil, and then adding immobilized lipase to react to obtain a reactant; (2) centrifuging reactants, collecting a light-phase product, carrying out molecular distillation, and collecting a heavy-phase product to obtain diglyceride; the immobilized lipase comprises lipase and a carrier, the carrier comprises loofah sponge, soybean meal and bentonite, and the mass ratio of the loofah sponge to the soybean meal to the bentonite is 1: (2-4): (3-6). The method has the advantages that the effects of reducing triglyceride, total cholesterol and uric acid are relatively good, and the yield and the purity are relatively high.

Methods for the use of prodrugs of itaconic acid and 1- and 4-methyl itaconic acid for inducing hair growth and treating an inflammatory, or immune activation (adaptive or innate), skin condition or other condition associated with hair loss are disclosed.

The invention relates to a nutritional composition. The nutritional composition comprises medium-chain and long-chain fatty acid triglyceride and nervonic acid in a mass ratio of (3: 1)-(1500: 1), and has a synergistic effect in the aspects of preventing or relieving diarrhea, inhibiting staphylococcus aureus in vivo or in vitro and / or preventing or treating inflammation. The invention also relates to a food product comprising said nutritional composition. The invention also relates to application of the nutritional composition in preparation of products with one or more purposes selected from 1) to 3): 1) preventing or relieving diarrhea; 2) inhibiting staphylococcus aureus in vivo or in vitro; and 3) preventing or treating inflammation.

The invention provides a nutritional composition and application of the nutritional composition. The nutritional composition comprises medium-chain and long-chain fatty acid triglyceride and a milk fat globule membrane in a mass ratio of (2: 1)-(97: 1), and the medium-chain and long-chain fatty acid triglyceride and the milk fat globule membrane have a synergistic effect in the aspects of promoting skeletal development, especially increasing bone mineral density and / or preventing or treating osteogenesis insufficiency and / or osteoporosis.

Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.

Compounds are provided having the following structure:or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R3, L1, L2, G1, G2 and G3 are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.

The invention relates to mRNA comprising lipid nanoparticles and their medical uses. The lipid nanoparticles of the present invention comprise a cationic lipid according to formula (I), (II) or (III) and / or a PEG lipid according to formula (IV), as well as an mRNA compound comprising an mRNA sequence encoding an antigenic peptide or protein. The invention further relates to the use of said lipid nanoparticles as vaccines or medicaments, in particular with respect to influenza or rabies vaccination.

The invention provides a nutritional composition and application of the nutritional composition. The nutritional composition comprises medium-chain and long-chain fatty acid triglyceride (MLCT) and milk fat globule membrane (MFGM) in a mass ratio of 2: 1 to 80: 1, and the combination of the two has the effects of synergistically improving diarrhea, inhibiting staphylococcus aureus in vivo or in vitro and / or regulating intestinal flora.

A bioenergy generator to increase the life force of a biological system is provided. The bioenergy generator includes fine pieces of natural stone, fine pieces of natural sand, fine pieces of metal, water and a supporting material operable to hold the natural sand, the natural stone, the metal, and the water together. Uses of the bioenergy generator are also provided, in particular, to enhance natural healing ability of a biological body and to treat a disease in a mammal, and to mitigate side effects of cancer treatments.

The invention belongs to the field of preparation of sedation maintaining agents, and particularly relates to a sedation maintaining agent administrated through oral mucosa and a preparation method of the sedation maintaining agent. Bamboo leaf polysaccharide and pigskin collagen peptide are heated and mixed with chlorogenic acid and butyl acetate under the catalytic action of lanthanum nitrate, and the obtained moisturizing adhesive has biocompatibility, can be stably adhered to oral mucosa and can promote salivary secretion of children; nanoparticles obtained through freeze spray drying are uniformly dispersed in a copolymer solution containing sodium salicylate and polyacrylate, and the obtained nervous system regulator can balance excitability of sympathetic nerves and parasympathetic nerves of children; the emotion relieving composition contains modified felwort powder obtained through esterification reaction, the modified felwort powder is mixed with a moisturizing adhesive and a nervous system regulator, and the prepared sedation maintaining medicament administrated through the oral mucosa protects oral health of children in the oral operation anesthesia process, is free of irritation, improves anxiety emotion and does not affect postoperative awakening.

The invention relates to the technical field of probiotics, in particular to a combined fungicide for improving Alzheimer's disease and application of the combined fungicide. The combined microbial agent is prepared from lactobacillus gasseri LFLG-245 and inactivated Ackermania muciniphila AKKLF (Ackermania muciniphila AKKLF); the lactobacillus gasseri LFLG-245 is preserved in the China General Microbiological Culture Collection Center on March 24, 2025, and the preservation number of the lactobacillus gasseri LFLG-245 is CGMCC (China General Microbiological Culture Collection Center) No.33952. The lactobacillus gasseri LFLG-245 has the advantages that the lactobacillus gasseri LFLG-245 is preserved in the China General Microbiological Culture Collection Center; the Akkermansia muciniphila AKKLF is preserved in the China General Microbiological Culture Collection Center on March 24, 2025, and the preservation number of the Akkermansia muciniphila AKKLF is CGMCC (China General Microbiological Culture Collection Center) No.33955. The Akkermansia muciniphila AKKLF disclosed by the invention has the advantages that the Akkermansia muciniphila AKKLF can be applied to the field of biological The combined microbial agent provided by the invention can improve the Alzheimer's disease.

Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.

The present invention is in the field of antioxidants and relates to cosmetic or pharmaceutical, preferably dermatological, compositions or homecare product comprising or consisting of a synergistic combination of a specific antioxidant and an effective amount of 1,2-heptanediol and / or 2,3-heptanediol or of a specific alkanediol or a mixture of two or more different specific alkanediols and the use of said compositions as a cosmetic, for personal care, as a pharmaceutical or homecare product, in particular for scavenging reactive oxygen species (ROS), for inhibition matrix metalloproteinases expression and / or for inhibiting interleukin 8 (IL-8) secretion. Additionally, the present invention relates to the use of 1,2-heptanediol and / or 2,3-heptanediol or of a specific alkanediol or a mixture of two or more different specific alkanediols for enhancing the antioxidative effect of an antioxidant in a cosmetic or pharmaceutical, preferably dermatological, composition or homecare product, and / or for enhancing the antioxidative effect of a cosmetic or pharmaceutical, preferably dermatological, composition upon application.

Disclosed is a topical anhydrous, homogenous pharmaceutical composition for treating skin disorder and wounds comprising cod liver oil, hempseed oil, monolaurin, medium chain triglycerides (“MCT”), free fatty acids, sea salt, and vegetable oil selected from the group consisting of red palm concentrate, coconut oil, and red palm oil and combination thereof and optionally fish collagen, ascorbyl palmitate, thickening agent, such as beeswax, red palm concentrate and cetyl ester.

The invention belongs to the technical field of grease preparation, and particularly relates to a preparation method and application of diglyceride oil with a weight reducing effect. Comprising the following steps: firstly, adding grease into a basic nutrient solution, adding strains for fermentation, and filtering to obtain a glycolysis product; adding glycerol into the glycolysis product, carrying out lipase esterification reaction, and carrying out centrifugal separation to obtain an oil phase; the method comprises the following steps: degrading triglyceride by adopting dominant strain fermentation, then adding glycerol, and carrying out esterification reaction under the action of dominant compound lipase to obtain the diglyceride oil. According to the method, the 1, 3-diglyceride can be selectively generated, the proportion of dominant grease of the 1, 3-diglyceride can be increased, and research shows that the prepared diglyceride oil has good weight reduction and fat reduction effects and has a good application prospect.

The invention discloses a method for preparing uric acid-reducing diglyceride through enzymolysis and a product and application thereof, and belongs to the technical field of diglyceride production, the method comprises the following steps: (1) mixing vegetable oil, glycerol, water and an enzyme preparation for reaction to obtain a reaction solution; (2) standing and layering the reaction liquid, and collecting supernatant; (3) performing distillation separation on the supernatant, and performing decoloration and deodorization to obtain diglyceride; the enzyme preparation in the step (1) is prepared from lipase Lipase, esterase Esterase and phospholipase C in a weight ratio of (5-10): (0.1-0.3): 1. Compared with the prior art, the method disclosed by the invention is simple and low in cost, and the prepared diglyceride has more advantages in the aspect of reducing uric acid.

The invention discloses a lutein ester microcapsule preparation process, which comprises: extracting a lutein ester solution, preparing marigold and n-hexane, washing marigold, removing soil and impurities, airing, and grinding into a fine powder with a mesh number of less than 200 mesh after airing. The lutein ester microcapsules are dried in a freeze-drying mode, the activity of the lutein ester microcapsules can be ensured, structural damage and deformation in the drying process are reduced, the embedding rate of the lutein ester microcapsules is increased, the stability and bioavailability of the lutein ester microcapsules can be improved by adding the coenzyme Q10 into the lutein ester solution, and the lutein ester microcapsules can be applied to preparation of capsules. According to the present invention, the lutein ester solution is added to the wall material, the oxidation degradation process of the lutein ester is delayed so as to improve the high temperature resistance, and the surfactant is added during the lutein ester solution and wall material mixing process so as to improve the solubility and the dispersibility of the lutein ester, such that the lutein ester can be well wrapped by the vegetable glue wall material, protection can be achieved, and the light resistance can be improved; and the shelf life is prolonged.

Compositions for inducing and maintaining a state of flow in a subject include optically pure S-beta-hydroxybutyrate or non-racemic mixtures enriched with the S-enantiomer. The S-beta-hydroxybutyrate enantiomer modulates the effect of ketone bodies in the subject and controls the rate at which ketosis is achieved. Beta-hydroxybutyric acid is more rapidly absorbed and utilized by the body than salts or esters, enhances taste, and reduces the need to include citric acid or other edible acids. Beta-hydroxybutyrate salts are more slowly absorbed and utilized by the body and can provide one or more electrolytes. Compositions for controlling ketone body level in a subject may contain a dietetically or pharmaceutically acceptable carrier and optically pure S-beta-hydroxybutyrate or non-racemic mixture enriched with S-beta-hydroxybutyrate, wherein the compositions contain from about 50.5% to 100% by enantiomeric equivalents of S-beta-hydroxybutyrate and from about 49.5% to 0% by enantiomeric equivalents of R-beta-hydroxybutyrate.

Compositions for delivering ketone bodies to a subject include one or more beta-hydroxybutyrate salts, one or more acetoacetate salts, beta-hydroxybutyric acid, and optionally acetoacetic acid. The compositions may optionally include one or more ketone body esters, such as one or more beta-hydroxybutyrate esters and / or one or more acetoacetate esters. An example composition contains about 2% to about 98% on a molar basis of the one or more beta-hydroxybutyrate salts and the one or more acetoacetate salts, about 2% to about 98% on a molar basis of the beta-hydroxybutyrate free acid and optionally the acetoacetate free acid, and optionally about 2% to about 98% on a molar basis of one or more ketone body esters.

The invention provides therapeutic methods, pharmaceutical compositions, and unit dose formulations for treating movement disorders, such as using a muscarinic acetylcholine receptor inhibitor in combination with a muscarinic acetylcholine receptor activator to treat dystonia. In some aspects, the invention provides a method of treating a movement disorder in a patient, where the method comprises administering to a patient in need thereof (i) a muscarinic acetylcholine receptor inhibitor in an amount effective to treat the movement disorder and (ii) a muscarinic acetylcholine receptor activator in an amount effective to reduce the frequency and / or magnitude of at least one side effect of the muscarinic acetylcholine receptor inhibitor, to thereby treat the movement disorder.

The invention relates to a nutritional composition, a food containing the nutritional composition and application of the nutritional composition. The nutritional composition comprises medium-chain and long-chain fatty acid triglyceride and nervonic acid, and the medium-chain and long-chain fatty acid triglyceride and the nervonic acid have a synergistic effect in the aspects of improving skeletal development and / or preventing or treating bone diseases.

Methods, compositions and kits comprising alpha-adrenergic antagonists, such as phentolamine, for the treatment of glaucoma, ocular hypertension, and / or other ocular disorders, such as non-arteritic anterior ischemic optic neuropathy or keratoconus, are provided. Said methods, compositions and kits may further comprise additional therapeutic agents, including prostaglandin analogues such as latanoprost, beta-adrenergic antagonists, alpha-adrenergic agonists, carbonic anhydrase inhibitors, cholinergic agonists, NMDA receptor antagonist, adenosine receptor antagonists, 5-HT2a receptor agonists, or Rho kinase inhibitors.